The Neuro-Ischaemic Charcot Foot: Prevalence, Characteristics and Severity of Peripheral Arterial Disease in Acute Charcot Neuro-Arthropathy

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Nov 11

PMID 36362457

Authors

Marco Meloni

Raju Ahluwalia

Alfonso Bellia

Enrico Brocco

Michela Di Venanzio

Aikaterini Andreadi

Laura Giurato

Valeria Ruotolo

Nicola Di Daniele

Davide Lauro

Luigi Uccioli

Affiliations

Soon will be listed here.

Abstract

The study aimed to evaluate the prevalence, characteristics and outcomes of patients affected by Charcot neuro-arthropathy (CN) and peripheral arterial disease (PAD) compared to CN without PAD. Consecutive patients presenting with an acute CN were included. The sample size was calculated by the power analysis by adopting the two-tailed tests of the null hypothesis with alfa = 0.05 and a value of beta = 0.10 as the second type error and, therefore, a test power equal to 90%. Seventy-six patients were identified. Twenty-four patients (31.6%) had neuro-ischaemic CN; they were older (66 vs. 57yrs), p = 0.03, had a longer diabetes duration (19 vs. 14yrs), p < 0.001, and more cases of end-stage-renal-disease (12.5 vs. 0%), p = 0.04 and ischaemic heart disease (58.3 vs. 15.4%), p < 0.0001 than neuropathic CN. Fifty patients (65.8%) had concomitant foot ulcers, 62.5% and 67.3% (p = 0.3), respectively, in CN with and without PAD. Neuro-ischaemic CN show arterial lesions of 2.9 vessels, and PAD was located predominantly below-the-knee (75%) but not below-the-ankle (16.7%). The outcomes for neuro-ischaemic and neuropathic CN patients were, respectively: wound healing (86.7 vs. 94.3%), p = 0.08; minor amputation (25 vs. 7.7%), p = 0.003; major amputation (8.3 vs. 1.9%), p = 0.001; hospitalization (75 vs. 23%), p = 0.0001. The study showed a frequent association between CN and PAD, leading to a neuro-ischaemic Charcot foot type. Neuro-ischaemic CN leaded to an increased risk of minor and major amputation and hospitalization, compared to neuropathic CN.

Citing Articles

Demographic and Clinical Characteristics of Patients With Charcot Neuro-Osteoarthropathy in People With Diabetes Mellitus in Six Countries: A Multicenter Observational Study From 1996 to 2022.

Jude E, Siafarikas C, Rastogi A, Bem R, Tankova T, Kong M J Diabetes Res. 2025; 2025():4275741.

PMID: 39817102 PMC: 11735061. DOI: 10.1155/jdr/4275741.

Charcot neuro-osteoarthropathy: a review of key concepts and an evidence-based surgical management algorithm.

Argyropoulos M, Wynell-Mayow W, Johnson O, Faroug R, Johal K, Deol R Front Clin Diabetes Healthc. 2024; 5:1344359.

PMID: 39219847 PMC: 11362032. DOI: 10.3389/fcdhc.2024.1344359.

Early Treatment of Acute Stage 0/1 Diabetic Charcot Foot Can Avoid Major Amputations at One Year.

Bittante C, Cerasari V, Bellizzi E, Ahluwalia R, Di Venanzio M, Giurato L J Clin Med. 2024; 13(6).

PMID: 38541859 PMC: 10970903. DOI: 10.3390/jcm13061633.

References

Rogers L, Frykberg R, Armstrong D, Boulton A, Edmonds M, Ha Van G . The Charcot foot in diabetes. J Am Podiatr Med Assoc. 2011; 101(5):437-46. DOI: 10.7547/1010437. View

Chantelau E, Richter A . The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging--a review of 71 cases. Swiss Med Wkly. 2013; 143:w13831. DOI: 10.4414/smw.2013.13831. View

Wukich D, Raspovic K, Suder N . Prevalence of Peripheral Arterial Disease in Patients With Diabetic Charcot Neuroarthropathy. J Foot Ankle Surg. 2016; 55(4):727-31. DOI: 10.1053/j.jfas.2016.01.051. View

Schaper N, van Netten J, Apelqvist J, Bus S, Hinchliffe R, Lipsky B . Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36 Suppl 1:e3266. DOI: 10.1002/dmrr.3266. View

Jude E, Oyibo S, Chalmers N, Boulton A . Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001; 24(8):1433-7. DOI: 10.2337/diacare.24.8.1433. View

Anichini R, Policardo L, Lombardo F, Salutini E, Tedeschi A, Viti S . Hospitalization for Charcot neuroarthropathy in diabetes: A population study in Italy. Diabetes Res Clin Pract. 2017; 129:25-31. DOI: 10.1016/j.diabres.2017.03.029. View

de Medeiros Nobrega M, Aras R, Martins Netto E, Couto R, Marinho A, da Silva J . Risk factors for Charcot foot. Arch Endocrinol Metab. 2015; 59(3):226-30. DOI: 10.1590/2359-3997000000042. View

Meloni M, Izzo V, Giurato L, Lazaro-Martinez J, Uccioli L . Prevalence, Clinical Aspects and Outcomes in a Large Cohort of Persons with Diabetic Foot Disease: Comparison between Neuropathic and Ischemic Ulcers. J Clin Med. 2020; 9(6). PMC: 7356179. DOI: 10.3390/jcm9061780. View

Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D . Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008; 51(5):747-55. PMC: 2292424. DOI: 10.1007/s00125-008-0940-0. View

10.

Hinchliffe R, Andros G, Apelqvist J, Bakker K, Friederichs S, Fiedrichs S . A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev. 2012; 28 Suppl 1:179-217. DOI: 10.1002/dmrr.2249. View

11.

Meloni M, Izzo V, Da Ros V, Morosetti D, Stefanini M, Brocco E . Characteristics and Outcome for Persons with Diabetic Foot Ulcer and No-Option Critical Limb Ischemia. J Clin Med. 2020; 9(11). PMC: 7700155. DOI: 10.3390/jcm9113745. View

12.

Forsythe R, Brownrigg J, Hinchliffe R . Peripheral arterial disease and revascularization of the diabetic foot. Diabetes Obes Metab. 2014; 17(5):435-44. DOI: 10.1111/dom.12422. View

13.

Sohn M, Lee T, Stuck R, Frykberg R, Budiman-Mak E . Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care. 2009; 32(5):816-21. PMC: 2671113. DOI: 10.2337/dc08-1695. View

14.

Jaff M, White C, Hiatt W, Fowkes G, Dormandy J, Razavi M . An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering.... Catheter Cardiovasc Interv. 2015; 86(4):611-25. DOI: 10.1002/ccd.26122. View

15.

Marco M, Valentina I, Daniele M, Valerio D, Andrea P, Roberto G . Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview. Curr Diabetes Rev. 2020; 17(4):474-485. DOI: 10.2174/1573399816999201001203111. View

16.

Aiello A, Anichini R, Brocco E, Caravaggi C, Chiavetta A, Cioni R . Treatment of peripheral arterial disease in diabetes: a consensus of the Italian Societies of Diabetes (SID, AMD), Radiology (SIRM) and Vascular Endovascular Surgery (SICVE). Nutr Metab Cardiovasc Dis. 2014; 24(4):355-69. DOI: 10.1016/j.numecd.2013.12.007. View

17.

Ahluwalia R, Armstrong D, Petrova N, Papanas N, Edmonds M . Stage 0 Charcot Neuroarthropathy in the Diabetic Foot: An Emerging Narrow Window of Opportunity?. Int J Low Extrem Wounds. 2021; 21(4):374-376. DOI: 10.1177/15347346211011844. View

18.

Ferraresi R, Mauri G, Losurdo F, Troisi N, Brancaccio D, Caravaggi C . BAD transmission and SAD distribution: a new scenario for critical limb ischemia. J Cardiovasc Surg (Torino). 2018; 59(5):655-664. DOI: 10.23736/S0021-9509.18.10572-6. View

19.

Uccioli L, Gandini R, Giurato L, Fabiano S, Pampana E, Spallone V . Long-term outcomes of diabetic patients with critical limb ischemia followed in a tertiary referral diabetic foot clinic. Diabetes Care. 2010; 33(5):977-82. PMC: 2858201. DOI: 10.2337/dc09-0831. View

20.

Wukich D, Sadoskas D, Vaudreuil N, Fourman M . Comparison of Diabetic Charcot Patients With and Without Foot Wounds. Foot Ankle Int. 2016; 38(2):140-148. DOI: 10.1177/1071100716673985. View